BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9309370)

  • 1. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
    Pession A; Prete A; Paolucci G
    Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer.
    Castagnola E; Lanino E; Giacchino R; Viscoli C; Dini G
    J Chemother; 1999 Feb; 11(1):54-60. PubMed ID: 10078782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients.
    Krcméry V; Koza I; Mardiak J; Fuchsberger P; Spánik S; Trupl J; Horníková M; Kusenda Z; Sufliarsky J; Svec J
    Chemotherapy; 1992; 38(1):74-6. PubMed ID: 1618007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftriaxone as a single agent in empirical therapy of unexplained fever in granulocytopenic children with solid tumors.
    Bartolozzi S; Clerico A; Properzi E; Minori A; Castello MA
    J Chemother; 1997 Jun; 9(3):227-31. PubMed ID: 9210007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study.
    Meunier F; Van der Auwera P; Aoun M; Ibrahim S; Tulkens PM
    J Antimicrob Chemother; 1991 May; 27 Suppl C():129-39. PubMed ID: 1856142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients.
    Borbolla JR; López-Hernández MA; González-Avante M; DeDiego J; Trueba E; Alvarado ML; Jiménez RM
    Chemotherapy; 2001; 47(5):381-4. PubMed ID: 11561142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients.
    Cudillo L; Masi M; Scimò MT; Tribalto M; Cantonetti M; Criscuolo D; Papa G
    J Chemother; 1989 Dec; 1(6):413-6. PubMed ID: 2614507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
    Liu CY; Wang FD
    Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Kern WV; Cometta A; De Bock R; Langenaeken J; Paesmans M; Gaya H
    N Engl J Med; 1999 Jul; 341(5):312-8. PubMed ID: 10423465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral administration of cefixime to lower risk febrile neutropenic children with cancer.
    Paganini HR; Sarkis CM; De Martino MG; Zubizarreta PA; Casimir L; Fernandez C; Armada AA; Rodriguez-Brieshcke MT; Debbag R
    Cancer; 2000 Jun; 88(12):2848-52. PubMed ID: 10870071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes.
    Rossini F; Pioltelli P; Bolis S; Borin L; Casaroli I; Lanzi E; Maffè P; Parma M; Tripputi P; Pogliani EM
    Clin Drug Investig; 1998; 15(5):425-33. PubMed ID: 18370498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
    Paganini H; Rodriguez-Brieshcke T; Zubizarreta P; Latella A; Firpo V; Casimir L; Armada A; Fernández C; Cáceres E; Debbag R
    Cancer; 2001 Apr; 91(8):1563-7. PubMed ID: 11301406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
    Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
    Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.
    Suwangool P; Aswapokee N; Sathapatayavongs B; Leelasuphasri S; Siritanaratkul N; Chuncharunee S; Chayakul P
    J Med Assoc Thai; 1993 Jun; 76(6):314-8. PubMed ID: 8083623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.